DS
OPNT

David Shaw’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

David Shaw’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,044
Closed -$120K – 5713
2022
Q2 		$120K Sell
10,044
-6,945
-41% -$112K ﹤0.01% 4691
2022
Q1 		$364K Buy
+16,989
New +$450K ﹤0.01% 4554

Other funds holding OPNT

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
ACA
Apis Capital Advisors New York $1.03B AUM 383.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's OPNT Position: Q3 2022 in Review

David Shaw sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q3 2022, closing a stake of 10,044 shares — an estimated $120K sold.

David Shaw first reported a position in OPNT in Q1 2022 and held it in 2 quarters. The position peaked at $364K in Q1 2022. 32 funds tracked by Wall St. Rank hold OPNT as of Q3 2022.

  • David Shaw reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 10,044 Opiant Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $120K.
  • David Shaw first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • David Shaw's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $364K in Q1 2022.
  • 32 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.